NexImmune (NEXI) Stock Price, News & Analysis

Company Overview

NexImmune, Inc. is a clinical‐stage biotechnology company focused on developing novel T‐cell immunotherapies to treat cancer, autoimmune disease and persistent viral infections. The company’s core innovation is its proprietary artificial thymic organoid (ATO) platform, which generates naïve T cells capable of recognizing specific antigens. By guiding T‐cell development in vitro, NexImmune aims to create targeted, high‐potency therapeutic candidates that leverage the body’s natural immune response.

The company’s pipeline includes multiple product candidates at various stages of development. Among these, NexImmune is advancing programs designed to target tumor‐associated antigens in solid tumors and hematologic malignancies. In parallel, the firm is exploring applications in chronic viral infections, including hepatitis B virus, and in certain autoimmune disorders where selective modulation of T‐cell responses may restore immune balance. Preclinical studies have demonstrated the ability of ATO‐derived T cells to expand and persist in vivo, laying the groundwork for early‐stage clinical trials.

Founded in 2015 and headquartered in Gaithersburg, Maryland, NexImmune went public on the NASDAQ under the ticker NEXI in mid‐2020. The company conducts its research and development activities in the United States, with ongoing collaborations and clinical trials spanning North America and select international sites. NexImmune’s management team comprises seasoned biotechnology executives and immunology researchers, many of whom have held leadership positions at leading cell therapy and gene therapy organizations.

As a clinical‐stage enterprise, NexImmune continues to expand its ATO platform capabilities, seeking to address high‐unmet‐need indications where current treatments offer limited benefit. With a strategic focus on partnerships and pipeline diversification, the company aims to translate its platform science into multiple off‐the‐shelf and personalized T‐cell therapies for patients worldwide.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $2.17
• Volume: 400 shs
• Average Volume: 643 shs
• Market Capitalization: $139.50
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NexImmune Stock Analysis - MarketRank™

NexImmune scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NexImmune.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of NexImmune has been sold short.

Short Interest Ratio / Days to Cover

NexImmune has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NexImmune does not currently pay a dividend.

Dividend Growth

NexImmune does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

NexImmune has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for NexImmune this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for NEXI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NexImmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.90% of the stock of NexImmune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.85% of the stock of NexImmune is held by institutions.

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/30/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NEXI
• CIK: 1538210
• Web: www.neximmune.com
• Phone: 301-825-9810
• Fax: N/A
• Employees: 70
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,395,000
• Free Float: 1,187,000
• Market Cap: $139.50
• Optionable: Not Optionable
• Beta: -1,915.44